Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients

Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients

BackgroundAddition of oxaliplatin to adjuvant 5-FU has significantly improved the disease-free survival and served as the first line adjuvant chemotherapy in advanced colorectal cancer (CRC) patients. However, a fraction of patients remains refractory to oxaliplatin-based treatment. It is urgent to...

Full description

Bibliographic Details
Main Authors: Khamushavalli Geevimaan, Jing-You Guo, Chia-Ning Shen, Jeng-Kai Jiang, Cathy S. J. Fann, Ming-Jing Hwang, Jr-Wen Shui, Hsiu-Ting Lin, Mei-Jung Wang, Hsuan-Cheng Shih, Anna Fen-Yau Li, Shih-Ching Chang, Shung-Haur Yang, Jeou-Yuan Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
patient-derived organoids (PDOs)
oxaliplatin sensitivity assessment
colorectal cancer
connectivity map
personalized chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.883437/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.883437/full

Similar Items